These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30256257)

  • 1. Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas.
    Bennett JA; Pesci A; Morales-Oyarvide V; Da Silva A; Nardi V; Oliva E
    Am J Surg Pathol; 2019 Feb; 43(2):235-243. PubMed ID: 30256257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.
    Bennett JA; Morales-Oyarvide V; Campbell S; Longacre TA; Oliva E
    Am J Surg Pathol; 2016 May; 40(5):656-63. PubMed ID: 26813747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.
    Köbel M; Tessier-Cloutier B; Leo J; Hoang LN; Gilks CB; Soslow RA; Delair D; Stewart CJR; Lee CH
    Int J Gynecol Pathol; 2017 Nov; 36(6):555-561. PubMed ID: 28114191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
    Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
    Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
    Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
    Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High homogeneity of MMR deficiency in ovarian cancer.
    Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
    Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 12. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 13. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
    Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
    Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.
    Lu FI; Gilks CB; Mulligan AM; Ryan P; Allo G; Sy K; Shaw PA; Pollett A; Clarke BA
    Int J Gynecol Pathol; 2012 Nov; 31(6):524-31. PubMed ID: 23018216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
    Backes FJ; Leon ME; Ivanov I; Suarez A; Frankel WL; Hampel H; Fowler JM; Copeland LJ; O'Malley DM; Cohn DE
    Gynecol Oncol; 2009 Sep; 114(3):486-90. PubMed ID: 19515405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.
    Joehlin-Price AS; Perrino CM; Stephens J; Backes FJ; Goodfellow PJ; Cohn DE; Suarez AA
    Gynecol Oncol; 2014 Apr; 133(1):43-7. PubMed ID: 24444820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
    Pasanen A; Loukovaara M; Bützow R
    Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma.
    Gayhart MG; Johnson N; Paul A; Quillin JM; Hampton LJ; Idowu MO; Smith SC
    Am J Clin Pathol; 2020 Nov; 154(6):792-801. PubMed ID: 32789450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.